IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis

I. B. McInnes, G. C. Illei, C. L. Danning, C. H. Yarboro, M. Crane, T. Kuroiwa, R. Schlimgen, E. Lee, B. Foster, D. Flemming, C. Prussin, T. A. Fleisher, D. T. Boumpas

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Psoriatic arthritis (PsA) provides an ideal disease model in which to investigate the bioactivities of potentially therapeutic cytokines at multiple sites of tissue inflammation. We investigated the effects of IL-10, an antiinflammatory cytokine, given s.c. for 28 days in a double-blind, placebo-controlled study in PsA patients. Synovial/skin biopsies, peripheral blood leukocytes, articular magnetic resonance images, and clinical disease activity scores were obtained sequentially. Modest, but significant clinical improvement in skin, but not articular disease activity scores with only minor adverse effects was observed. Type 1, but not type 2 T cell cytokine production in vitro was suppressed in human rIL-10 compared with placebo recipients. Similarly, monokine production in vitro was reduced, whereas serum soluble TNFRII levels were elevated, indicating suppression of monocyte function. Decreased T cell and macrophage infiltration in synovial tissues was accompanied by reduced P-selectin expression. Moreover, suppressed synovial enhancement on magnetic resonance imaging and reduced α v β 3 integrin expression on von Willebrand factor + vessels were observed. Together these data demonstrate that a short course of IL-10 modulates immune responses in vivo via diverse effects on endothelial activation, and leukocyte recruitment and effector function. Such biological changes may result in clinically meaningful improvement in disease activity.

Original languageEnglish (US)
Pages (from-to)4075-4082
Number of pages8
JournalJournal of Immunology
Volume167
Issue number7
DOIs
StatePublished - Oct 1 2001

Fingerprint

Psoriatic Arthritis
Skin Diseases
Interleukin-10
Leukocytes
Cytokines
Joints
Placebos
Monokines
T-Lymphocytes
Skin
P-Selectin
von Willebrand Factor
Integrins
Monocytes
Anti-Inflammatory Agents
Magnetic Resonance Spectroscopy
Macrophages
Magnetic Resonance Imaging
Inflammation
Biopsy

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

McInnes, I. B., Illei, G. C., Danning, C. L., Yarboro, C. H., Crane, M., Kuroiwa, T., ... Boumpas, D. T. (2001). IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Journal of Immunology, 167(7), 4075-4082. https://doi.org/10.4049/jimmunol.167.7.4075
McInnes, I. B. ; Illei, G. C. ; Danning, C. L. ; Yarboro, C. H. ; Crane, M. ; Kuroiwa, T. ; Schlimgen, R. ; Lee, E. ; Foster, B. ; Flemming, D. ; Prussin, C. ; Fleisher, T. A. ; Boumpas, D. T. / IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. In: Journal of Immunology. 2001 ; Vol. 167, No. 7. pp. 4075-4082.
@article{ae0136c185d84fa3b9ae70d677db41fd,
title = "IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis",
abstract = "Psoriatic arthritis (PsA) provides an ideal disease model in which to investigate the bioactivities of potentially therapeutic cytokines at multiple sites of tissue inflammation. We investigated the effects of IL-10, an antiinflammatory cytokine, given s.c. for 28 days in a double-blind, placebo-controlled study in PsA patients. Synovial/skin biopsies, peripheral blood leukocytes, articular magnetic resonance images, and clinical disease activity scores were obtained sequentially. Modest, but significant clinical improvement in skin, but not articular disease activity scores with only minor adverse effects was observed. Type 1, but not type 2 T cell cytokine production in vitro was suppressed in human rIL-10 compared with placebo recipients. Similarly, monokine production in vitro was reduced, whereas serum soluble TNFRII levels were elevated, indicating suppression of monocyte function. Decreased T cell and macrophage infiltration in synovial tissues was accompanied by reduced P-selectin expression. Moreover, suppressed synovial enhancement on magnetic resonance imaging and reduced α v β 3 integrin expression on von Willebrand factor + vessels were observed. Together these data demonstrate that a short course of IL-10 modulates immune responses in vivo via diverse effects on endothelial activation, and leukocyte recruitment and effector function. Such biological changes may result in clinically meaningful improvement in disease activity.",
author = "McInnes, {I. B.} and Illei, {G. C.} and Danning, {C. L.} and Yarboro, {C. H.} and M. Crane and T. Kuroiwa and R. Schlimgen and E. Lee and B. Foster and D. Flemming and C. Prussin and Fleisher, {T. A.} and Boumpas, {D. T.}",
year = "2001",
month = "10",
day = "1",
doi = "10.4049/jimmunol.167.7.4075",
language = "English (US)",
volume = "167",
pages = "4075--4082",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

McInnes, IB, Illei, GC, Danning, CL, Yarboro, CH, Crane, M, Kuroiwa, T, Schlimgen, R, Lee, E, Foster, B, Flemming, D, Prussin, C, Fleisher, TA & Boumpas, DT 2001, 'IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis', Journal of Immunology, vol. 167, no. 7, pp. 4075-4082. https://doi.org/10.4049/jimmunol.167.7.4075

IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. / McInnes, I. B.; Illei, G. C.; Danning, C. L.; Yarboro, C. H.; Crane, M.; Kuroiwa, T.; Schlimgen, R.; Lee, E.; Foster, B.; Flemming, D.; Prussin, C.; Fleisher, T. A.; Boumpas, D. T.

In: Journal of Immunology, Vol. 167, No. 7, 01.10.2001, p. 4075-4082.

Research output: Contribution to journalArticle

TY - JOUR

T1 - IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis

AU - McInnes, I. B.

AU - Illei, G. C.

AU - Danning, C. L.

AU - Yarboro, C. H.

AU - Crane, M.

AU - Kuroiwa, T.

AU - Schlimgen, R.

AU - Lee, E.

AU - Foster, B.

AU - Flemming, D.

AU - Prussin, C.

AU - Fleisher, T. A.

AU - Boumpas, D. T.

PY - 2001/10/1

Y1 - 2001/10/1

N2 - Psoriatic arthritis (PsA) provides an ideal disease model in which to investigate the bioactivities of potentially therapeutic cytokines at multiple sites of tissue inflammation. We investigated the effects of IL-10, an antiinflammatory cytokine, given s.c. for 28 days in a double-blind, placebo-controlled study in PsA patients. Synovial/skin biopsies, peripheral blood leukocytes, articular magnetic resonance images, and clinical disease activity scores were obtained sequentially. Modest, but significant clinical improvement in skin, but not articular disease activity scores with only minor adverse effects was observed. Type 1, but not type 2 T cell cytokine production in vitro was suppressed in human rIL-10 compared with placebo recipients. Similarly, monokine production in vitro was reduced, whereas serum soluble TNFRII levels were elevated, indicating suppression of monocyte function. Decreased T cell and macrophage infiltration in synovial tissues was accompanied by reduced P-selectin expression. Moreover, suppressed synovial enhancement on magnetic resonance imaging and reduced α v β 3 integrin expression on von Willebrand factor + vessels were observed. Together these data demonstrate that a short course of IL-10 modulates immune responses in vivo via diverse effects on endothelial activation, and leukocyte recruitment and effector function. Such biological changes may result in clinically meaningful improvement in disease activity.

AB - Psoriatic arthritis (PsA) provides an ideal disease model in which to investigate the bioactivities of potentially therapeutic cytokines at multiple sites of tissue inflammation. We investigated the effects of IL-10, an antiinflammatory cytokine, given s.c. for 28 days in a double-blind, placebo-controlled study in PsA patients. Synovial/skin biopsies, peripheral blood leukocytes, articular magnetic resonance images, and clinical disease activity scores were obtained sequentially. Modest, but significant clinical improvement in skin, but not articular disease activity scores with only minor adverse effects was observed. Type 1, but not type 2 T cell cytokine production in vitro was suppressed in human rIL-10 compared with placebo recipients. Similarly, monokine production in vitro was reduced, whereas serum soluble TNFRII levels were elevated, indicating suppression of monocyte function. Decreased T cell and macrophage infiltration in synovial tissues was accompanied by reduced P-selectin expression. Moreover, suppressed synovial enhancement on magnetic resonance imaging and reduced α v β 3 integrin expression on von Willebrand factor + vessels were observed. Together these data demonstrate that a short course of IL-10 modulates immune responses in vivo via diverse effects on endothelial activation, and leukocyte recruitment and effector function. Such biological changes may result in clinically meaningful improvement in disease activity.

UR - http://www.scopus.com/inward/record.url?scp=0035478652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035478652&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.167.7.4075

DO - 10.4049/jimmunol.167.7.4075

M3 - Article

C2 - 11564829

AN - SCOPUS:0035478652

VL - 167

SP - 4075

EP - 4082

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -